Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

s and 19.1 months, respectively.

"Data show that some people with CLL who have 17p abnormalities may have poor outcomes and may not respond as well to standard chemotherapeutic agents," said lead investigator Michael Fiegl, MD, Department of Internal Medicine, Academic Natters Hospital, Natters, Austria. "This analysis showed activity in patients across all cytogenetic categories -- including high risk patients with 17p deletion and in patients where conventional chemotherapy has failed. The results of this analysis warrant further prospective, clinical studies in patients with 17p deletion."

A second study (abstract #2095) evaluated a combination of cyclophosphamide, fludarabine, alemtuzumab (Campath) and rituximab (CFAR) as a frontline therapy in high-risk CLL patients. Of the 48 patients evaluated in this ongoing trial, 28 percent had 17p deletion. In the total cohort, treatment with the CFAR regimen resulted in an ORR of 94 percent and a CRR of 69 percent. In patients with 17p deletion, treatment with the CFAR regimen resulted in an ORR of 77 percent and a CRR of 54 percent.

"Patients with 17p deletion who have active disease and need treatment are at high risk for lower complete and overall remission rate, shorter progression-free and overall survival," said lead investigator William G. Wierda, MD, PhD, assistant professor of medicine, M.D. Anderson Cancer Center, Houston, Texas. "In this analysis, Campath in combination with the FCR regimen showed activity in previously untreated patients with 17p deletion. The CFAR regimen may be a viable first-line therapy for patients in this population, although further study is warranted."

In a third multicenter study (abstract #329) of 103 CLL patients who were fludarabine refractory, unfavorable genetics were frequent (17p deletion: 29 percent, 11q deletion: 19 percent, unmutated IgVH: 68 percent, TP53 mutation: 34 percent). In this
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer ... VPHM).   As a result of the waiver, ... Shire expects to complete the tender offer on January 24, ... satisfaction of all of the remaining conditions to the tender ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/14/2014)... COLUMBUS, Ohio Heart patients with beliefs about health ... to skip sessions of cardiac rehabilitation, new research suggests. ... number of these beliefs referred to as "irrational ... was associated with lower adherence to a prescribed ... assessed: Doubting the preventive power of the flu vaccine ...
(Date:4/14/2014)... A new study shows that domestic abuse is ... depression and post-traumatic stress disorder (PTSD), in mothers. ... abuse are associated with specific mental health problems. ... Carolina State University, Simon Fraser University and the ... see whether and how intimate partner abuse ...
(Date:4/14/2014)... to treatment guidelines for high-risk bladder cancer, chemotherapy ... in routine clinical practice. The findings are published ... journal of the American Cancer Society. , Clinical ... patients with muscle-invasive bladder cancer who are given ... whether chemotherapy after surgery also improves survival. To ...
(Date:4/13/2014)... force has created a new definition for epilepsy that ... disease. The study published in Epilepsia , a ... League Against Epilepsy (ILAE), provides a greater level of ... unprovoked seizures, and those with one unprovoked seizure and ... , The 2005 report by the ILAE task force ...
(Date:4/11/2014)... there is still no effective medical treatment. In an ... of a schizophrenic person, researchers from the University of ... rats that have been given hallucinogenic drugs. This may ... Seven per cent of the adult population suffers from ... understand the disease, they still do not know what ...
Breaking Medicine News(10 mins):Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3Health News:Study links domestic abuse to mental health problems in new mothers 2Health News:New clinical definition for epilepsy improves diagnosis accuracy 2Health News:Protein researches closing in on the mystery of schizophrenia 2Health News:Protein researches closing in on the mystery of schizophrenia 3
... say , WEDNESDAY, Nov. 14 (HealthDay News) -- U.S. scientists ... in cancer cells. , They found that genes in cancer ... structures called nucleosomes within the cells. , "The study shows ... in cancer cells. It identifies what the target looks like, ...
... other partners and donors share in success, ... National,Pediatric Brain Tumor Consortium headquarters, Chili,s Care ... for exceptional patient care, MEMPHIS, Tenn., Nov. ... Grill & Bar(R) celebrated the national,grand opening of ...
... Toy Drive to Benefit Shands Jacksonville-Marks Grand Opening ... Bank will,officially dedicate its new Mandarin branch today ... will attend the,grand opening event this morning, which ... opening of the facility and the,Company,s expanded presence ...
... With half of dogs and cats over age 10 dying of cancer, ... free oncology consultations ... any pet., BOISE, Idaho, Nov. 14 When Jack Stephens, DVM, ... emotional support from his small dog, Spanky. Recognizing that,cancer now claims the ...
... Be Held in Conjunction with Inaugural Gala, NORTH ... the National Patient Safety Foundation today announced that it ... 7-8, 2008 in,Boston, Massachusetts. The Institute, established by NPSF ... strategic paths and calls to action for,the field of ...
... initials? Most people do and, as past research has shown, ... For example, Jack is more likely to move to Jacksonville ... to move to Philadelphia and marry Phyllis. Scientists call this ... enough to encourage the pursuit of name-resembling life outcomes and ...
Cached Medicine News:Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:CapitalSouth Bank Officially Opens Three of Four New Locations in Jacksonville 2Health News:CapitalSouth Bank Officially Opens Three of Four New Locations in Jacksonville 3Health News:All Pets With Cancer in U.S. Provided Free Consultation 2Health News:All Pets With Cancer in U.S. Provided Free Consultation 3Health News:All Pets With Cancer in U.S. Provided Free Consultation 4Health News:Lucian Leape Institute Announces First Roundtable 2Health News:Lucian Leape Institute Announces First Roundtable 3Health News:What's in a name? Initials linked to success, study shows 2
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: